Baseline Renal Function Predicts Hyponatremia in Liver Cirrhosis Patients Treated with Terlipressin for Variceal Bleeding
Table 1
Baseline characteristics of the study population.
Characteristics
Hyponatremia ()
Control ()
value
Age (years)
56.3 ± 10.3
57.5 ± 11.3
0.421
Males, n (%)
73 (83)
146 (83)
1.000
Etiology of cirrhosis, n (%)
Alcohol
55 (62.5)
97 (55.1)
0.252
Hepatitis B virus
27 (30.7)
83 (47.2)
0.011
Hepatitis C virus
6 (6.8)
6 (4.5)
0.437
Concomitant complications of cirrhosis, n (%)
Ascites
66 (75)
123 (69.9)
0.385
Hepatic encephalopathy
18 (20.5)
46 (26.1)
0.310
Spontaneous bacterial peritonitis
3 (3.4)
15 (8.5)
0.120
Hepatocellular carcinoma, n (%)
26 (29.5)
51 (29)
0.924
BCLC stage A/B/C/D, n (%)
7/6/3/10 (27/23/12/38)
8/7/11/25 (16/14/22/48)
0.336
Diabetes mellitus, n (%)
17 (19.3)
(47.9)
0.029
Hypertension, n (%)
14 (15.9)
16 (9.1)
0.093
Hemoglobin, g/dL
9.5 ± 2.0
9.2 ± 8.2
0.822
Bilirubin, mg/dL
2.3 ± 1.9
5.6 ± 7.6
<0.001
Albumin, g/dL
3.0 ± 0.6
2.8 ± 0.6
0.006
INR
1.6 ± 0.5
2.0 ± 1.2
0.001
Creatinine, mg/dL
0.8 ± 0.4
1.6 ± 1.4
<0.001
Initial sodium, mEq
137.8 ± 4.5
134.1 ± 7.2
<0.001
Lowest sodium, mEq
125.9 ± 6.8
137.2 ± 7.8
<0.001
MELD score
14.0 ± 5.0
20.7 ± 10.2
<0.001
Child-Pugh score
8.3 ± 2.3
9.5 ± 2.7
0.001
Shock on admission, n (%)
4 (4.5)
45 (34.3)
<0.001
Blood transfusion (packed red cells)
3.2 ± 2.2
3.9 ± 3.6
0.118
Cumulative dose of terlipressin (mg)
17.9 ± 3.8
17.6 ± 7.5
0.621
Amount of free water hydration (L)
4.7 ± 2.3
4.05 ± 3.9
0.142
BCLC: Barcelona Clinic Liver Cancer; INR: international normalized ratio; MELD: Model for End-Stage Liver Disease; the data are expressed as the means ± the standard deviations (ranges) or numbers (%).
